Accueil › Cancer du poumon › Missouri › Kansas City
Essais cliniques pour Cancer du poumon à Kansas City, MO
19 études pour Cancer du poumon recherchent des participants dans et autour de Kansas City (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
The Vanguard Study: Testing a New Way to Screen for Cancer
Recrutement en coursVolontaires sains bienvenus
- Saint Luke's Hospital of Kansas City, Kansas City
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Recrutement en coursPhase 3
- Kansas City Veterans Affairs Medical Center, Kansas City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Recrutement en coursPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Kansas City Veterans Affairs Medical Center, Kansas City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Recrutement en coursPhase 3
- University Health Truman Medical Center, Kansas City
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Recrutement en coursPhase 1
- St. Lukes Hospital of Kansas City, Kansas City
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Recrutement en coursPhase 3
- The University of Kansas Cancer Center, Westwood · à 5 mi
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Recrutement en coursPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Recrutement en coursPhase 1/2
- University of Kansas Hospital-Westwood Cancer Center, Westwood · à 5 mi
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Recrutement en coursPhase 3
- The University of Kansas Cancer Center - Westwood, Westwood · à 5 mi
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- University of Kansas Hospital-Westwood Cancer Center, Westwood · à 5 mi
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Recrutement en coursPhase 3
- University of Kansas Cancer Center - North, Kansas City
Integrated Cancer Repository for Cancer Research
Recrutement en coursÉtude observationnelleVolontaires sains bienvenus
- Saint Luke's Cancer Institute, East, Kansas City
- Saint Luke's Cancer Institute, Kansas City
- Saint Luke's Cancer Institute, Kansas City North, Kansas City
- et 1 autres
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Recrutement en coursPhase 1/2
- The University of Kansas Cancer Center, Westwood · à 5 mi
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- et 1 autres
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2/3
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- Kansas City Veterans Affairs Medical Center, Kansas City
- et 2 autres
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- University Health Truman Medical Center, Kansas City
- University of Kansas Cancer Center - Briarcliff, Kansas City
- University of Kansas Cancer Center - North, Kansas City
- et 1 autres
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Kansas City
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Recrutement en coursÉtude observationnelle
- Saint Lukes Hospital, Kansas City
Essais pour Cancer du poumon dans d'autres villes
- Houston, TX78 études
- Boston, MA62 études
- New York City, NY60 études
- Los Angeles, CA45 études
- Arlington, VA41 études
- Washington, DC41 études
- Chicago, IL41 études
- Baltimore, MD40 études
- Nashville, TN40 études
- St. Louis, MO39 études
- Columbus, OH37 études
- Philadelphia, PA36 études
Autres études à Kansas City
- Cancer du sein34 études
- Cancer du poumon non à petites cellules31 études
- Insuffisance cardiaque25 études
- Cancer (tous types)21 études
- Cancer colorectal16 études
- Cancer métastatique15 études
- Leucémie aiguë myéloïde15 études
- Cancer de la prostate14 études
- Cancer de l'ovaire11 études
- Obésité11 études
- Diabète de type 211 études
- Maladie cardiovasculaire11 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.